Published in Exp Mol Med on June 30, 2010
Toll-like receptor 4 activation in cancer progression and therapy. Clin Dev Immunol (2011) 1.14
NK cells: key to success of DC-based cancer vaccines? Oncologist (2012) 0.98
Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol (2012) 0.91
Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic. Chonnam Med J (2015) 0.87
Cellular immunotherapy using dendritic cells against multiple myeloma. Korean J Hematol (2012) 0.83
Optimal culture conditions for the generation of natural killer cell-induced dendritic cells for cancer immunotherapy. Cell Mol Immunol (2011) 0.82
Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity. Oncotarget (2015) 0.81
Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells. Sci Rep (2014) 0.80
Cellular uptake of exogenous calcineurin B is dependent on TLR4/MD2/CD14 complexes, and CnB is an endogenous ligand of TLR4. Sci Rep (2016) 0.75
Combination therapy with dendritic cells and lenalidomide is an effective approach to enhance antitumor immunity in a mouse colon cancer model. Oncotarget (2017) 0.75
Anti-tumor Activity of Toll-Like Receptor 7 Agonists. Front Pharmacol (2017) 0.75
An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J Immunol Methods (1999) 17.06
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
A blast from the past: clearance of apoptotic cells regulates immune responses. Nat Rev Immunol (2002) 8.79
Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med (1982) 5.47
Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett (2003) 5.27
CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol (2004) 5.02
Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med (2002) 4.67
Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med (2002) 4.32
Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol (2002) 3.45
Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J Exp Med (2002) 3.35
Functional interactions between dendritic cells and NK cells during viral infection. Nat Immunol (2002) 3.20
An absolute and restricted requirement for IL-12 in natural killer cell IFN-gamma production and antiviral defense. Studies of natural killer and T cell responses in contrasting viral infections. J Immunol (1996) 3.09
NK cell and DC interactions. Trends Immunol (2004) 2.68
APC-independent activation of NK cells by the Toll-like receptor 3 agonist double-stranded RNA. J Immunol (2004) 2.65
The first 1000 dendritic cell vaccinees. Cancer Invest (2003) 2.44
CpG and double-stranded RNA trigger human NK cells by Toll-like receptors: induction of cytokine release and cytotoxicity against tumors and dendritic cells. Proc Natl Acad Sci U S A (2004) 2.23
Dendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function. J Immunol (2003) 2.17
TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol (2005) 1.83
Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood (2004) 1.71
A contribution of mouse dendritic cell-derived IL-2 for NK cell activation. J Exp Med (2004) 1.59
Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J Clin Invest (1998) 1.30
The direct effects of Toll-like receptor ligands on human NK cell cytokine production and cytotoxicity. Cell Immunol (2006) 1.30
Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine. Cancer Immunol Immunother (2007) 1.29
Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood (2005) 1.21
Helper role of NK cells during the induction of anticancer responses by dendritic cells. Mol Immunol (2005) 1.19
Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol Immunother (2001) 1.16
Improving vaccines by targeting antigens to dendritic cells. Exp Mol Med (2009) 1.16
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors. Clin Cancer Res (2006) 1.16
Ins and outs of dendritic cells. Int Arch Allergy Immunol (2006) 1.16
Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol Immunother (2004) 1.15
Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res (1984) 1.14
Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother (2003) 1.07
Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. Cancer (2007) 1.02
In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy. J Immunol (2004) 0.98
Mechanism of antimetastatic immunopotentiation by low-dose cyclophosphamide. Eur J Cancer (2000) 0.84
Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. Cell Immunol (2001) 0.82
A novel dendritic cell-based cancer vaccine produces promising results in a syngenic CC-36 murine colon adenocarcinoma model. J Surg Res (2007) 0.81
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol (2007) 2.70
Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer (2011) 2.59
Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography. Circulation (2003) 2.37
Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. Blood (2005) 2.27
Hax1-mediated processing of HtrA2 by Parl allows survival of lymphocytes and neurons. Nature (2008) 2.10
Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer. Eur J Nucl Med Mol Imaging (2012) 2.04
S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial. Lancet Oncol (2012) 1.98
Previous best responses can be re-achieved by resumption after imatinib discontinuation in patients with chronic myeloid leukemia: implication for intermittent imatinib therapy. Leuk Lymphoma (2009) 1.86
A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun (2006) 1.63
Induction of multiple myeloma-specific cytotoxic T lymphocyte stimulation by dendritic cell pulsing with purified and optimized myeloma cell lysates. Leuk Lymphoma (2007) 1.55
Ability of mature dendritic cells to interact with regulatory T cells is imprinted during maturation. Cancer Res (2008) 1.53
Tumour-infiltrating T-cell subpopulations in glioblastomas. Br J Neurosurg (2011) 1.49
Biosynthesis of the allylmalonyl-CoA extender unit for the FK506 polyketide synthase proceeds through a dedicated polyketide synthase and facilitates the mutasynthesis of analogues. J Am Chem Soc (2010) 1.49
Pilot trial of yttrium-90 ibritumomab tiuxetan consolidation following rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone chemotherapy in patients with limited-stage, bulky diffuse large B-cell lymphoma. Leuk Lymphoma (2011) 1.43
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome. Acta Haematol (2015) 1.42
Genetically engineered Salmonella typhimurium as an imageable therapeutic probe for cancer. Cancer Res (2009) 1.38
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood (2006) 1.36
Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. J Clin Oncol (2009) 1.35
Molecular imaging of the kinetics of vascular endothelial growth factor gene expression in ischemic myocardium. Circulation (2004) 1.33
TMPRSS4 induces invasion and epithelial-mesenchymal transition through upregulation of integrin alpha5 and its signaling pathways. Carcinogenesis (2010) 1.30
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica (2008) 1.27
Towards pathogenomics: a web-based resource for pathogenicity islands. Nucleic Acids Res (2006) 1.24
Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma. Eur J Cancer (2011) 1.23
Spectra of chromosomal aberrations in 325 leukemia patients and implications for the development of new molecular detection systems. J Korean Med Sci (2011) 1.23
Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea. Jpn J Clin Oncol (2013) 1.22
Incidental focal F-18 FDG accumulation in lung parenchyma without abnormal CT findings. Ann Nucl Med (2009) 1.19
Annexin A3 is a potential angiogenic mediator. Biochem Biophys Res Commun (2005) 1.18
Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II study. Haematologica (2010) 1.16
Noninvasive real-time imaging of tumors and metastases using tumor-targeting light-emitting Escherichia coli. Mol Imaging Biol (2007) 1.16
Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study. BMC Cancer (2010) 1.14
Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther (2010) 1.12
Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer (2011) 1.12
Impact of medication discontinuation on increased intestinal FDG accumulation in diabetic patients treated with metformin. AJR Am J Roentgenol (2010) 1.11
Analysis of intracellular short organic acid-coenzyme A esters from actinomycetes using liquid chromatography-electrospray ionization-mass spectrometry. J Mass Spectrom (2007) 1.10
Annexin A4 interacts with the NF-kappaB p50 subunit and modulates NF-kappaB transcriptional activity in a Ca2+-dependent manner. Cell Mol Life Sci (2010) 1.09
Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol (2005) 1.09
A case of secondary myocardial lymphoma presenting with ventricular tachycardia. J Korean Med Sci (2002) 1.09
Clinical significance of clonality and Epstein-Barr virus infection in adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol (2010) 1.09
Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability. Gastroenterology (2012) 1.09
A genome-wide scan for the Sasang constitution in a Korean family suggests significant linkage at chromosomes 8q11.22-23 and 11q22.1-3. J Altern Complement Med (2009) 1.08
Dynamic changes in DNA methylation and hydroxymethylation when hES cells undergo differentiation toward a neuronal lineage. Hum Mol Genet (2013) 1.08
Comparison of [14C]FMAU, [3H]FEAU, [14C]FIAU, and [3H]PCV for monitoring reporter gene expression of wild type and mutant herpes simplex virus type 1 thymidine kinase in cell culture. Mol Imaging Biol (2006) 1.07
Poor prognostic significance of Mycobacterium tuberculosis infection during bortezomib-containing chemotherapy in patients with multiple myeloma. Blood Res (2013) 1.06
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. Ann Hematol (2009) 1.06
Clinical efficacy and prediction of response to granulocyte transfusion therapy for patients with neutropenia-related infections. Haematologica (2004) 1.05
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study. Ann Hematol (2009) 1.05
The atypical orphan nuclear receptor DAX-1 interacts with orphan nuclear receptor Nur77 and represses its transactivation. Mol Endocrinol (2004) 1.04
Clinicopathologic characteristics of gastric carcinoma in elderly patients: a comparison with young patients. World J Gastroenterol (2005) 1.04
ZEB2 upregulates integrin α5 expression through cooperation with Sp1 to induce invasion during epithelial-mesenchymal transition of human cancer cells. Carcinogenesis (2012) 1.03
Transthyretin-related proteins function to facilitate the hydrolysis of 5-hydroxyisourate, the end product of the uricase reaction. FEBS Lett (2005) 1.03
Identification of caspase-3 degradome by two-dimensional gel electrophoresis and matrix-assisted laser desorption/ionization-time of flight analysis. Proteomics (2004) 1.03
Identification of a serodiagnostic antigen, legumain, by immunoproteomic analysis of excretory-secretory products of Clonorchis sinensis adult worms. Proteomics (2009) 1.01
Treatment outcomes with CHOP chemotherapy in adult patients with hemophagocytic lymphohistiocytosis. J Korean Med Sci (2008) 1.01
Immunological characterization of glioblastoma cells for immunotherapy. Anticancer Res (2013) 1.01
The prognostic significance of tumor human papillomavirus status for patients with anal squamous cell carcinoma treated with combined chemoradiotherapy. Int J Cancer (2011) 1.00
Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer. Cancer Chemother Pharmacol (2010) 1.00
Association of a common genetic variant in prostate stem-cell antigen with gastric cancer susceptibility in a Korean population. Mol Carcinog (2011) 0.99
Regulation of fur expression by RpoS and fur in Vibrio vulnificus. J Bacteriol (2003) 0.99
Estrogen-related receptor γ (ERRγ) is a novel transcriptional regulator of phosphatidic acid phosphatase, LIPIN1, and inhibits hepatic insulin signaling. J Biol Chem (2011) 0.99
Engineering of bacteria for the visualization of targeted delivery of a cytolytic anticancer agent. Mol Ther (2013) 0.99
The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res (2008) 0.99
HSP70 deficiency results in activation of c-Jun N-terminal Kinase, extracellular signal-regulated kinase, and caspase-3 in hyperosmolarity-induced apoptosis. J Biol Chem (2004) 0.98
Co-chaperone CHIP promotes aggregation of ataxin-1. Mol Cell Neurosci (2006) 0.98
Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol (2014) 0.98
Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells. Int J Oncol (2009) 0.98
NSC-87877, inhibitor of SHP-1/2 PTPs, inhibits dual-specificity phosphatase 26 (DUSP26). Biochem Biophys Res Commun (2009) 0.98
Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype. J Clin Oncol (2011) 0.98
Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas. Br J Haematol (2007) 0.97
Protein-protein interaction networks: from interactions to networks. J Biochem Mol Biol (2004) 0.96
Prognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemia. Korean J Hematol (2010) 0.96